Adjuvant denosumab in early breast-cancer

Giuseppina Campisi; Alberto Bedogni; Vittorio Fusco

Adjuvant denosumab in early breast-cancer

Giuseppina Campisi, Alberto Bedogni, Vittorio Fusco

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Article

Abstract

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

Lingua originale	English
pagine (da-a)	e124-
Numero di pagine	1
Rivista	LANCET ONCOLOGY
Volume	21
Stato di pubblicazione	Published - 2020

Fingerprint

All Science Journal Classification (ASJC) codes

Oncology

Cita questo

Campisi, G., Bedogni, A., & Fusco, V. (2020). Adjuvant denosumab in early breast-cancer. LANCET ONCOLOGY, 21, e124-.

@article{2c6b96ebd3794573bc6aec6388c85b60,

title = "Adjuvant denosumab in early breast-cancer",

abstract = "We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).",

author = "Giuseppina Campisi and Alberto Bedogni and Vittorio Fusco",

year = "2020",

language = "English",

volume = "21",

pages = "e124--",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Adjuvant denosumab in early breast-cancer

AU - Campisi, Giuseppina

AU - Bedogni, Alberto

AU - Fusco, Vittorio

PY - 2020

Y1 - 2020

N2 - We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

AB - We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

UR - http://hdl.handle.net/10447/408720

M3 - Article

VL - 21

SP - e124-

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

ER -

Accesso al documento

OA Link